HPM Web Site

  • HPM Web Site

About

Authors

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader

Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2008 Hyman, Phelps & McNamara, P.C.

Blogroll

« “Male Enhancement” Dietary Supplement Distributor Gets Sentencing Enhancement -- 25 Years for Fraud | Main | FDA Clarifies that FDAAA Clinical Trial Certification Requirement Applies to IND Submissions; Questions Remain About ANDA Bioequivalence Study Registration »

September 03, 2008

CBI’s Pharmaceutical Congress on Paragraph IV Disputes

Kurt R. Karst of Hyman, Phelps & McNamara, P.C. (and co-chief blogger of FDALawBlog.net) will be speaking at the Center for Business Intelligence’s Pharmaceutical Congress on Paragraph IV Disputes, October 15 - 16, 2008, at the Marriott Philadelphia Downtown in Philadelphia, Pennsylvania.  A copy of the program is available here.  At the event, preeminent members of the nation’s Food and Drug Bar will address a broad range of topics, including: 

  • FTC address on pharmaceutical antitrust
  • In depth analysis of recent court cases and their implications on brand and generic companies
  • Effects of KSR on brand and generic litigation strategies
  • Panel discussion on acceptable settlement strategies for paragraph IV disputes
  • Litigating paragraph IV disputes with multiple ANDA filers
  • Interpreting forfeiture provisions for better business decisions
  • Pre-suit preparedness strategies for paragraph IV disputes
  • Citizen petitions and their impact on generic entry
  • Declaratory judgments
  • At-risk launches

For more information or to register, please contact the Center for Business Intelligence toll-free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.

Posted at 04:50 PM in Miscellaneous |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef00e554fc22ea8834

Listed below are links to weblogs that reference CBI’s Pharmaceutical Congress on Paragraph IV Disputes :

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.